A18.3
Tuberculosis of intestines, peritoneum and mesenteric glands
Clinical Classification Guidelines
Medical Intelligence & Overview
Tuberculosis (TB) is a contagious bacterial infection caused by *Mycobacterium tuberculosis*. While most commonly affecting the lungs, TB can also invade other parts of the body, including the intestines, peritoneum (lining of the abdominal cavity), and mesenteric glands (lymph nodes in the abdominal area). This form of TB, designated by ICD-10 code A18.3, poses unique health challenges due to its location and symptoms. Proper understanding of this condition is vital for recognizing its signs and ensuring timely treatment.
Causes & Symptoms
Clinical Causes: Transmission through inhalation of airborne droplets containing *Mycobacterium tuberculosis* Spread from a primary lung infection via the bloodstream or lymphatic system to abdominal organs Ingestion of contaminated food or milk containing TB bacteria (less common in majority of cases) Infection in immunocompromised individuals, making them more susceptible Close contact with someone who has active TB, facilitating transmission
Key Symptoms: Persistent abdominal pain or discomfort Unexplained weight loss and fatigue Fever, often low-grade and persistent Night sweats Loss of appetite Swelling or palpable masses in the abdomen Changes in bowel habits, such as diarrhea or constipation Nausea or vomiting Signs of intestinal obstruction in advanced cases Peritoneal involvement may lead to abdominal distension and tenderness
Diagnostic & Treatment
Diagnosis Path: Diagnosing TB of the intestines, peritoneum, and mesenteric glands involves a combination of clinical evaluation and specialized tests, including: - Physical examination to detect abdominal tenderness, masses, or signs of fluid accumulation - Imaging studies like abdominal X-rays, ultrasound, CT scans to identify abnormalities or fluid - Laboratory tests including sputum analysis if pulmonary TB is suspected - Blood tests such as Interferon-Gamma Release Assays (IGRAs) or Tuberculin Skin Test (TST) - Biopsy of affected tissue or lymph nodes to identify TB bacteria under a microscope - Microbiological cultures from tissue samples to confirm the presence of *Mycobacterium tuberculosis*
Treatment Protocols: Treatment typically involves a prolonged course of multiple antibiotics aimed at combating *Mycobacterium tuberculosis*. The regimen often includes: - An initial intensive phase with drugs such as isoniazid, rifampicin, pyrazinamide, and ethambutol - A continuation phase with isoniazid and rifampicin for several months to ensure complete eradication - Regular monitoring for drug efficacy and potential side effects - Supportive care for symptoms, such as pain management or nutritional support - In some cases, surgical intervention may be necessary to manage complications like bowel obstruction or abscesses Adherence to the full course of therapy is crucial to prevent relapse and development of drug-resistant TB strains.
Clinical Advice & FAQs
Billing Guidance
Is A18.3 a billable ICD-10 code?
Yes, A18.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report A18.3?
Clinical documentation must specify the nature of Tuberculosis of intestines, peritoneum and mesenteric glands and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
